Targeting bacterial RNA polymerase: Promises for future antisense antibiotics development

Infectious Disorders - Drug Targets

Volumn 11, Issue 2, 2011, Pages 175-187

  Bai, Hui ^a   Zhou, Ying ^a   Hou, Zheng ^a   Xue, Xiaoyan ^a   Meng, Jingru ^a   Luo, Xiaoxing ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Antisense antibiotics; Bacterial RNA polymerase; Sigma factor

Indexed keywords

ABI 0043; ANTIBIOTIC AGENT; BACTERIAL RNA POLYMERASE; CALOTHRIXIN; CBR 703; CORRALOPYRONIN A; ENZYME INHIBITOR; ETNANGIEN; FIDAXOMICIN; GE 23077; MICROCIN J25; MYXOPYRONIN; PAROMOMYCIN; PYRROTHINE DERIVATIVE; RIFABUTIN; RIFALAZIL; RIFAMPICIN; RIFAPENTINE; RIFAXIMIN; RIPOSTATIN A; RNA; RNA POLYMERASE; RNA POLYMERASE INHIBITOR; SALINAMIDE; SORANGICIN; STREPTOLYDIGIN; TAGETITOXIN; TOLYPOMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UREIDOTHIOPHENE;

ARTICLE; BACTERICIDAL ACTIVITY; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME STRUCTURE; GENE EXPRESSION; GRAM NEGATIVE BACTERIUM; HUMAN; NONHUMAN; PROTEIN ANALYSIS; PROTEIN ASSEMBLY; PROTEIN FUNCTION; RNA SYNTHESIS; SCREENING TEST; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EID: 79955029522     PISSN: 18715265     EISSN: None     Source Type: Journal    
DOI: 10.2174/187152611795589708     Document Type: Article

References (101)

1. Chopra, I. Bacterial RNA polymerase: a promising target for the discovery of new antimicrobial agents. Curr. Opin. Investig. Drugs., 2007, 8(8), 600-607.
2. Villain-Guillot, P.; Bastide, L.; Gualtieri, M.; Leonetti, J. P. Progress in targeting bacterial transcription. Drug Discov Today, 2007, 12(5-6), 200-208.
3. Sousa, R. Tie me up, tie me down: inhibiting RNA polymerase. Cell, 2008, 135(2), 205-207.
4. Severinov, K. RNA polymerase structure-function: insights into points of transcriptional regulation. Curr. Opin. Microb., 2000, 3(2), 118-125.
5. Cramer, P. Multisubunit RNA polymerases, Current Opinion in Structural Biology. Curr. Opin. Struc. Biol., 2002, 12(1), 89-97.
6. Lane, W. J.; Darst, S. A. Molecular Evolution of Multisubunit RNA Polymerases: Structural Analysis. J. Mol. Biol., 2010, 395(4), 686-704.
7. Kireeva, M.; Kashlev, M.; Burton, Z. F. Translocation by multisubunit RNA polymerases. Biochim. Biophys. Acta., 2005, 1799(5-6), 389-401.
8. Strath, M.; Scott-Finnigan, T.; Gardner, M.; Williamson, D.; Wilson, I. Antimalarial activity of rifampicin in vitro and in rodent models. T Roysoctrop Med H, 2003, 87(2), 211-216.
9. Mukherjee, R.; Chatterji, D. Stationary phase induced alterations in mycobacterial RNA polymerase assembly: A cue to its phenotypic resistance towards rifampicin. Biochem Bioph Res Co, 2008, 369(3), 899-904.
10. Ho, M. X.; Hudson, B. P.; Das, K.; Arnold, E.; Ebright, R. H. Structures of RNA polymerase-antibiotic complexes. Curr. Opin. Struct. Biol., 2009, 19(6), 715-723.
11. Thomson, C. J.; Power, E.; Ruebsamen-Waigmann, H.; Labischinski, H. Antibacterial research and development in the 21st Century-an industry perspective of the challenges. Curr. Opin. Microb., 2004, 7(5), 445-450.
12. Projan, S. J. New (and not so new) antibacterial targets-from where and when will the novel drugs come? Curr. Opin. Pharmacol., 2002, 2(5), 513-522.
13. Chalker, A. F.; Lunsford, R. D. Rational identification of new antibacterial drug targets that are essential for viability using a genomics-based approach. Pharmacol. Therapeut., 2002, 95(1), 1-20.
14. Barker, J. J. Antibacterial drug discovery and structure-based design. Drug Discov. Today, 2006, 11(9-10), 391-404.
15. Artsimovitch, I.; Vassylyev, D. G. Is it easy to stop RNA polymerase? Cell. Cycle., 2006, 5(4), 399-404.
16. Borukhov, S.; Nudler, E. RNA polymerase: the vehicle of transcription. Trends Microbiol., 2008, 16(3), 126-134.
17. Darst, A. Bacterial RNA polymerase. Curr. Opin. Struc. Biol., 2001, 11(2), 155-162.
18. Svetlov, V.; Nudler, E. Macromolecular micromovements: how RNA polymerase translocates. Curr. Opin. Struc. Biol., 2009, 19(6), 701-707.
19. Seibold, S. A.; Singh, B. N.; Zhang, C.; Kireeva, M.; Domecq, C.; Bouchard, A.; Nazione, A. M.; Feig, M.; Cukier, R. I.; Coulombe, B.; Kashlev, M.; Hampsey, M.; Burton, Z. F. Conformational coupling, bridge helix dynamics and active site dehydration in catalysis by RNA polymerase. Biochim. Biophys. Acta., 2010, 1799(8), 575-587.
20. Burley, S. K.; Kamada, K. Transcription factor complexes. Curr. Opin. Struc. Biol., 2002, 12(2), 225-230.
21. Xue, X. C.; Liu, F.; Ou-Yang, Z. C. A Kinetic Model of Transcription Initiation by RNA Polymerase. J. Mol. Biol., 2008, 378(3), 520-529.
22. Ferguson, A. L.; Hughes, A. D.; Tufail, U.; Baumann, C. G.; Scott, D. J.; Hoggett, J. G. Interaction of [sigma]70 with Escherichia coli RNA polymerase core enzyme studied by surface plasmon resonance. FEBS Lett., 2000, 481(3), 281-284.
23. Naryshkin, N.; Revyakin, A.; Kim, Y.; Mekler, V.; Ebright, R. H. Structural Organization of the RNA Polymerase-Promoter Open Complex. Cell, 2000, 101(6), 601-611.
24. Ross, W.; Gourse, R. L. Analysis of RNA polymerase-promoter complex formation. Methods, 2009, 47(1), 13-24.
25. Campbell, E. A.; Westblade, L. F.; Darst, S. A. Regulation of bacterial RNA polymerase [sigma] factor activity: a structural perspective. Curr. Opin. Microb., 2008, 11(2), 121-127.
26. Kamiya, H.; Suzuki, A.; Yamaguchi, Y.; Handa, H.; Harashima, H. Incorporation of 8-hydroxyguanosine (8-oxo-7,8-dihydroguanosine) 5'-triphosphate by bacterial and human RNA polymerases. Free. Radical. Bio. Med., 2009, 46(12), 1703-1707.
27. Brueckner, F.; Ortiz, J.; Cramer, P. A movie of the RNA polymerase nucleotide addition cycle. Curr. Opin. Struc. Biol., 2009, 19(3), 294-299.
28. Vassylyev, D. G.; Vassylyeva, M. N.; Zhang, J.; Palangat, M.; Artsimovitch, I.; Landick, R. Structural basis for substrate loading in bacterial RNA polymerase. Nature, 2007, 448(7150), 163-168.
29. Bai, L.; Shundrovsky, A.; Wang, M. D. Sequence-dependent Kinetic Model for Transcription Elongation by RNA Polymerase. J. Mol. Biol., 2004, 344(2), 335-349.
30. Raffaelle, M.; Kanin, E. I.; Vogt, J.; Burgess, R. R.; Ansari, A. Z. Holoenzyme Switching and Stochastic Release of Sigma Factors from RNA Polymerase In Vivo. Mol. Cell, 2005, 20(3), 357-366.
31. Ring, B. Z.; Yarnell, W. S.; Roberts, J. W. Function of E. coli RNA Polymerase [sigma] Factor-[sigma]70 in Promoter-Proximal Pausing. Cell, 1996, 86(3), 485-493.
32. Vassylyev, D. G. Elongation by RNA polymerase: a race through roadblocks. Curr. Opin. Struc. Biol., 2009, 19(6), 691-700.
33. Ederth, J.; Mooney, R. A.; Isaksson, L. A.; Landick, R. Functional interplay between the jaw domain of bacterial RNA polymerase and allele-specific residues in the product RNA-binding pocket. J. Mol. Biol., 2006, 356(5), 1163-1179.
34. Mukhopadhyay, J.; Kapanidis, A. N.; Mekler, V.; Kortkhonjia, E.; Ebright, Y. W.; Ebright, R. H. Translocation of [sigma]70 with RNA Polymerase during Transcription: Fluorescence Resonance Energy Transfer Assay for Movement Relative to DNA. Cell, 2001, 106(4), 453-463.
35. Ades, S. E. Control of the alternative sigma factor [sigma] E in Escherichia coli. Curr. Opin. Microb., 2004, 7(2), 157-162.
36. Paget, M. S.; Helmann, J. D. The sigma70 family of sigma factors. Genome Biol., 2003, 4(1), 203.
37. Andre, E.; Bastide, L.; Michaux-Charachon, S.; Gouby, A.; Villain-Guillot, P.; Latouche, J.; Bouchet, A.; Gualtieri, M.; Leonetti, J. P. Novel synthetic molecules targeting the bacterial RNA polymerase assembly. J. Antimicrob. Chemother., 2006, 57(2), 245-251.
38. Arhin, F.; Belanger, O.; Ciblat, S.; Dehbi, M.; Delorme, D.; Dietrich, E.; Dixit, D.; Lafontaine, Y.; Lehoux, D.; Liu, J.; McKay, G. A.; Moeck, G.; Reddy, R.; Rose, Y.; Srikumar, R.; Tanaka, K. S.; Williams, D. M.; Gros, P.; Pelletier, J.; Parr, T. R., Jr.; Far, A. R. A new class of small molecule RNA polymerase inhibitors with activity against rifampicin-resistant Staphylococcus aureus. Bioorg. Med. Chem., 2006, 14(17), 5812-5832.
39. Krakow, J. S.; Anand Kumar, S. Inhibitors of bacterial DNAdependent RNA polymerase, Pharmacology & Therapeutics. Part A: Chemotherapy. Pharmacol. Therapeu., 1978, 2(2), 261-280.
40. Mariani, R.; Maffioli, S. I. Bacterial RNA polymerase inhibitors: an organized overview of their structure, derivatives, biological activity and current clinical development status. Curr. Med. Chem., 2009, 16(4), 430-454.
41. Artsimovitch, I.; Vassylyeva, M. N.; Svetlov, D.; Svetlov, V.; Perederina, A.; Igarashi, N.; Matsugaki, N.; Wakatsuki, S.; Tahirov, T. H.; Vassylyev, D. G. Modulation of the RNA Polymerase Catalytic Reaction Is an Essential Component of Transcription Control by Rifamycins. Cell, 2005, 122(3), 351-363.
42. Marsili, L.; Franceschi, G.; Ballabio, M.; Oronzo, G.; Vigevani, A.; Ungheri, D.; Della, B. C.; Sanfilippo, A. Novel rifamycins. III. Synthesis and antibacterial activity of 3-amidino-and of 4-aminoimidazolo[4,5-c] rifamycin derivatives. J. Antibiot. (Tokyo), 1983, 36(11), 1495-1501.
43. Clancy, C. J.; Yu, Y. C.; Lewin, A.; Nguyen, M. H. Inhibition of RNA synthesis as a therapeutic strategy against Aspergillus and Fusarium: demonstration of in vitro synergy between rifabutin and amphotericin B. Antimicrob. Agents Chemother., 1998, 42(3), 509-513.
44. Rothstein, D. M.; Shalish, C.; Murphy, C. K.; Sternlicht, A.; Campbell, L. A. Development potential of rifalazil and other benzoxazinorifamycins. Expert. Opin. Investig. Drugs, 2006, 15(6), 603-623.
45. Talpaert, M.; Campagnari, F.; Clerici, L. Lipiarmycin: An antibiotic inhibiting nucleic acid polymerases. Biochem Bioph Res Co, 1975, 63(1), 328-334.
46. Tupin, A.; Gualtieri, M.; Leonetti, J. P.; Brodolin, K. The transcription inhibitor lipiarmycin blocks DNA fitting into the RNA polymerase catalytic site. EMBO J., 2010, 29(15), 2527-2537.
47. Gualtieri, M.; Villain-Guillot, P.; Latouche, J.; Leonetti, J. P.; Bastide, L. Mutation in the Bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin. Antimicrob. Agents Chemother., 2006, 50(1), 401-402.
48. Johnson, A. P. Drug evaluation: OPT-80, a narrow-spectrum macrocyclic antibiotic. Curr. Opin. Investig. Drugs, 2007, 8(2), 168-173.
49. Mariani, R.; Granata, G.; Maffioli, S. I.; Serina, S.; Brunati, C.; Sosio, M.; Marazzi, A.; Vannini, A.; Patel, D.; White, R.; Ciabatti, R. Antibiotics GE23077, novel inhibitors of bacterial RNA polymerase. Part 3: Chemical derivatization. Bioorg. Med. Chem. Lett., 2005, 15(16), 3748-3752.
50. Sarubbi, E.; Monti, F.; Corti, E.; Miele, A.; Selva, E. Mode of action of the microbial metabolite GE23077, a novel potent and selective inhibitor of bacterial RNA polymerase. Eur. J. Biochem., 2004, 271(15), 3146-3154.
51. Temiakov, D.; Zenkin, N.; Vassylyeva, M. N.; Perederina, A.; Tahirov, T. H.; Kashkina, E.; Savkina, M.; Zorov, S.; Nikiforov, V.; Igarashi, N.; Matsugaki, N.; Wakatsuki, S.; Severinov, K.; Vassylyev, D. G. Structural Basis of Transcription Inhibition by Antibiotic Streptolydigin. Mol. Cell, 2005, 19(5), 655-666.
52. Tuske, S.; Sarafianos, S. G.; Wang, X.; Hudson, B.; Sineva, E.; Mukhopadhyay, J.; Birktoft, J. J.; Leroy, O.; Ismail, S.; Clark, J.; Dharia, C.; Napoli, A.; Laptenko, O.; Lee, J.; Borukhov, S.; Ebright, R. H.; Arnold, E. Inhibition of Bacterial RNA Polymerase by Streptolydigin: Stabilization of a Straight-Bridge-Helix Active-Center Conformation. Cell, 2005, 122(4), 541-552.
53. Olano, C.; Gómez, C.; Pérez, M.; Palomino, M.; Pineda-Lucena, A.; Carbajo, R. J.; Braña, A. F.; Méndez, C.; Salas, J. A. Deciphering Biosynthesis of the RNA Polymerase Inhibitor Streptolydigin and Generation of Glycosylated Derivatives. Chem Biol, 2009, 16(10), 1031-1044.
54. Campbell, E. A.; Pavlova, O.; Zenkin, N.; Leon, F.; Irschik, H.; Jansen, R.; Severinov, K.; Darst, S. A. EMBO J., 2005, 24(4), 674-682.
55. Adelman, K.; Yuzenkova, J.; La, P. A.; Zenkin, N.; Lee, J.; Lis, J. T.; Borukhov, S.; Wang, M. D.; Severinov, K. Molecular mechanism of transcription inhibition by peptide antibiotic Microcin J25. Mol. Cell, 2004, 14(6), 753-762.
56. Mukhopadhyay, J.; Sineva, E.; Knight, J.; Levy, R. M.; Ebright, R. H. Mol. Antibacterial Peptide Microcin J25 Inhibits Transcription by Binding within and Obstructing the RNA Polymerase Secondary Channel. Cell, 2004, 14(6), 739-751.
57. Wilson, K. A.; Kalkum, M.; Ottesen, J.; Yuzenkova, J.; Chait, B. T.; Landick, R.; Muir, T.; Severinov, K.; Darst, S. A. Structure of microcin J25, a peptide inhibitor of bacterial RNA polymerase, is a lassoed tail. J. Am. Chem. Soc., 2003, 125(41), 12475-12483.
58. Irschik, H.; Augustiniak, H.; Gerth, K.; Hofle, G.; Reichenbach, H. The ripostatins, novel inhibitors of eubacterial RNA polymerase isolated from myxobacteria. J. Antibiot. (Tokyo), 1995, 48(8), 787-792.
59. Le Foulon, F. X.; Braud, E.; Fabis, F.; Lancelot, J. C.; Rault, S. Solution-phase parallel synthesis of a 1140-member ureidothiophene carboxylic acid library. J. Comb. Chem., 2005, 7(2), 253-257.
60. Doundoulakis, T.; Xiang, A. X.; Lira, R.; Agrios, K. A.; Webber, S. E.; Sisson, W.; Aust, R. M.; Shah, A. M.; Showalter, R. E.; Appleman, J. R.; Simonsen, K. B. Myxopyronin B analogs as inhibitors of RNA polymerase, synthesis and biological evaluation. Bioorg. Med. Chem. Lett., 2004, 14(22), 5667-5672.
61. Lira, R.; Xiang, A. X.; Doundoulakis, T.; Biller, W. T.; Agrios, K. A.; Simonsen, K. B.; Webber, S. E.; Sisson, W.; Aust, R. M.; Shah, A. M.; Showalter, R. E.; Banh, V. N.; Steffy, K. R.; Appleman, J. R. Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase. Bioorg. Med. Chem. Lett., 2007, 17(24), 6797-6800.
62. Mukhopadhyay, J.; Das, K.; Ismail, S.; Koppstein, D.; Jang, M.; Hudson, B.; Sarafianos, S.; Tuske, S.; Patel, J.; Jansen, R.; Irschik, H.; Arnold, E.; Ebright, R. H. The RNA polymerase "switch region" is a target for inhibitors. Cell, 2008, 135(2), 295-307.
63. Vassylyev, D. G.; Svetlov, V.; Vassylyeva, M. N.; Perederina, A.; Igarashi, N.; Matsugaki, N.; Wakatsuki, S.; Artsimovitch, I. Structural basis for transcription inhibition by tagetitoxin. Nat. Struct. Mol. Biol., 2005, 12(12), 1086-1093.
64. Menche, D.; Li, P.; Irschik, H. Design, synthesis and biological evaluation of simplified analogues of the RNA polymerase inhibitor etnangien. Bioorg. Med. Chem. Lett., 2010, 20(3), 939-941.
65. Doan, N. T.; Stewart, P. R.; Smith, G. D. Inhibition of bacterial RNA polymerase by the cyanobacterial metabolites 12-epihapalindole E isonitrile and calothrixin A. FEMS Microbiol Lett, 2001, 196(2), 135-139.
66. Lambert, P. A. Bacterial resistance to antibiotics: Modified target sites. Adv Drug Deliver Rev, 2005, 57(10), 1471-1485.
67. Xu, M.; Zhou, Y. N.; Goldstein, B. P.; Jin, D. J. Cross-resistance of Escherichia coli RNA polymerases conferring rifampin resistance to different antibiotics. J. Bacteriol., 2005, 187(8), 2783-2792.
68. Jin, D. J.; Cashel, M.; Friedman, D. I.; Nakamura, Y.; Walter, W. A.; Gross, C. A. Effects of rifampicin resistant rpoB mutations on antitermination and interaction with nusA in Escherichia coli. J. Mol. Biol., 1988, 204(2), 247-261.
69. Jin, D. J.; Walter, W. A.; Gross, C. A. Characterization of the termination phenotypes of rifampicin-resistant mutants. J. Mol. Biol., 1988, 202(2), 245-253.
70. Jin, D. J.; Gross, C. A. Mapping and sequencing of mutations in the Escherichia coli rpoB gene that lead to rifampicin resistance. J. Mol. Biol., 1988, 202(1), 45-58.
71. Severinov, K.; Soushko, M.; Goldfarb, A.; Nikiforov, V. RifR mutations in the beginning of the Escherichia coli rpoB gene. Mol. Gen. Genet., 1994, 244(2), 120-126.
72. Nie, Y.; Viola, C.; Bieniossek, C.; Trowitzsch, S.; Vijay-Achandran, L. S.; Chaillet, M.; Garzoni, F.; Berger, I. Getting a grip on complexes. Curr. Genomics, 2009, 10(8), 558-572.
73. Rossolini, G. M.; Thaller, M. C. Coping with antibiotic resistance: contributions from genomics. Genome Med., 2010, 2(2), 15.
74. Butler, M. S.; Buss, A. D. Natural products--The future scaffolds for novel antibiotics? Biochem Pharmacol, 2006, 71(7), 919-929.
75. Kurreck, J. Nucleic acids chemistry and biology. Angew. Chem. Int. Ed Engl., 2003, 42(44), 5384-5385.
76. Kurreck, J. Improvement through novel chemical modifications. Eur. J. Biochem., 2003, 270(8), 1628-1644.
77. Frieden, M.; Orum, H. Locked nucleic acid holds promise in the treatment of cancer. Curr. Pharm. Des, 2008, 14(11), 1138-1142.
78. Wiessler, M.; Waldeck, W.; Pipkorn, R.; Kliem, C.; Lorenz, P.; Fleischhacker, H.; Hafner, M.; Braun, K. Extension of the PNA world by functionalized PNA monomers eligible candidates for inverse Diels Alder Click Chemistry. Int. J. Med. Sci., 2010, 7(4), 213-223.
79. Greenberg, D. E.; Marshall-Batty, K. R.; Brinster, L. R.; Zarember, K. A.; Shaw, P. A.; Mellbye, B. L.; Iversen, P. L.; Holland, S. M.; Geller, B. L. Antisense phosphorodiamidate morpholino oligomers targeted to an essential gene inhibit Burkholderia cepacia complex. J. Infect. Dis., 2010, 201(12), 1822-1830.
80. Devi, G. R.; Beer, T. M.; Corless, C. L.; Arora, V.; Weller, D. L.; Iversen, P. L. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin. Cancer Res., 2005, 11(10), 3930-3938.
81. Zhao, X.; Pan, F.; Holt, C. M.; Lewis, A. L.; Lu, J. R. Controlled delivery of antisense oligonucleotides: a brief review of current strategies. Expert. Opin. Drug Deliv., 2009, 6(7), 673-686.
82. Wancewicz, E. V.; Maier, M. A.; Siwkowski, A. M.; Albertshofer, K.; Winger, T. M.; Berdeja, A.; Gaus, H.; Vickers, T. A.; Bennett, C. F.; Monia, B. P.; Griffey, R. H.; Nulf, C. J.; Hu, J.; Corey, D. R.; Swayze, E. E.; Kinberger, G. A. Peptide nucleic acids conjugated to short basic peptides show improved pharmacokinetics and antisense activity in adipose tissue. J. Med. Chem., 2010, 53(10), 3919-3926.
83. Skoblov, M. I. Prospects of antisense therapy technologies. Mol. Biol. (Mosk), 2009, 43(6), 984-998.
84. Zamecnik, P. Background of the antisense oligonucleotide approach to chemotherapy. Antisense Nucleic Acid Drug Dev., 1997, 7(3), 199-202.
85. Wright, G. D. Making sense of antisense in antibiotic drug discovery. Cell Host Microbe, 2009, 6(3), 197-198.
86. Woodford, N.; Wareham, D. W. Tackling antibiotic resistance: a dose of common antisense? J. Antimicrob. Chemother., 2009, 63(2), 225-229.
87. Jin, D. J.; Cabrera, J. E. Coupling the distribution of RNA polymerase to global gene regulation and the dynamic structure of the bacterial nucleoid in Escherichia coli. J. Struc. Biol., 2006, 156(2), 284-291.
88. Anderson, W. F. Structural genomics and drug discovery for infectious diseases. Infect. Disord. Drug Targets, 2009, 9(5), 507-517.
89. Shao, Y.; Wu, Y.; Chan, C. Y.; McDonough, K.; Ding, Y. Rational design and rapid screening of antisense oligonucleotides for prokaryotic gene modulation. Nucleic Acids Res., 2006, 34(19), 5660-5669.
90. Shi, F.; Hoekstra, D. Effective intracellular delivery of oligonucleotides in order to make sense of antisense. J. Control Release, 2004, 97(2), 189-209.
91. Feklistov, A.; Darst, S. A. Promoter recognition by bacterial alternative sigma factors: the price of high selectivity? Genes Dev., 2009, 23(20), 2371-2375.
92. Campbell, E. A.; Muzzin, O.; Chlenov, M.; Sun, J. L.; Olson, C. A.; Weinman, O.; Trester-Zedlitz, M. L.; Darst, S. A. Structure of the bacterial RNA polymerase promoter specificity sigma subunit. Mol. Cell, 2002, 9(3), 527-539.
93. Zenkin, N.; Kulbachinskiy, A.; Yuzenkova, Y.; Mustaev, A.; Bass, I.; Severinov, K.; Brodolin, K. Region 1.2 of the RNA polymerase sigma subunit controls recognition of the-10 promoter element. EMBO J., 2007, 26(4), 955-964.
94. Mooney, R. A.; Landick, R. Tethering sigma70 to RNA polymerase reveals high in vivo activity of sigma factors and sigma70-dependent pausing at promoter-distal locations. Genes Dev., 2003, 17(22), 2839-2851.
95. Aristoff, P. A.; Garcia, G. A.; Kirchhoff, P. D.; Hollis Showalter, H. D. Rifamycins-Obstacles and opportunities. Tuberculosis, 2010, 90(2), 94-118.
96. Furtado, G. H.; Nicolau, D. P. Overview perspective of bacterial resistance. Expert. Opin. Ther. Pat, 2010, 20(10), 1273-1276.
97. Schmid, M. B. Crystallizing new approaches for antimicrobial drug discovery. Biochem Pharmacol, 2006, 71(7), 1048-1056.
98. Borukhov, S.; Nudler, E. RNA polymerase holoenzyme: structure, function and biological implications. Curr. Opin. Microb., 2003, 6(2), 93-100.
99. Ha, K. S.; Toulokhonov, I.; Vassylyev, D. G.; Landick, R. The NusA N-Terminal Domain Is Necessary and Sufficient for Enhancement of Transcriptional Pausing via Interaction with the RNA Exit Channel of RNA Polymerase. J. Mol. Biol., 2010, 401(5), 708-725.
100. Mooney, R. A.; Darst, S. A.; Landick, R. Sigma and RNA polymerase: an on-again, off-again relationship? Mol. Cell, 2005, 20(3), 335-345.
101. Murakami, K. S.; Darst, S. A. Bacterial RNA polymerases: the wholo story. Curr. Opin. Struct. Biol., 2003, 13(1), 31-39.